Cart
sales@molnova.com
Befetupitant
CAS No. 290296-68-3
Befetupitant( —— )
Catalog No. M33285 CAS No. 290296-68-3
Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 745 | Get Quote |
|
| 5MG | 1017 | Get Quote |
|
| 10MG | 1235 | Get Quote |
|
| 25MG | 1578 | Get Quote |
|
| 50MG | 2006 | Get Quote |
|
| 100MG | 2520 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBefetupitant
-
NoteResearch use only, not for human use.
-
Brief DescriptionBefetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.
-
DescriptionBefetupitant is a high-affinity, nonpeptide, competitive tachykinin 1 receptor (NK1R) antagonist.
-
In Vitro——
-
In VivoBefetupitant, a different, highly selective NK1R antagonist, is tested in the alkali burn model. Topical application of Befetupitant for 4 days is effective (P<0.05) in reducing hemangiogenesis and lymphangiogenesis at both concentrations (0.4 and 1.6 mg/mL). Befetupitant and its vehicle DMSO, however, induced corneal opacity even in healthy controls, as observed at slit-lamp examination. Moreover, fluorescein and hematoxylin-eosin staining showed epithelial damage and inflammatory cellular infiltration in the stroma, respectively, confirming DMSO toxicity. Topical application of Befetupitant reduces corneal neovascularization (CNV) in the alkali burn model but is toxic owing to the vehicle (DMSO); hence, Befetupitant is not tested in the suture model.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetNeurokinin Receptor
-
RecptorNeurokinin receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number290296-68-3
-
Formula Weight565.55
-
Molecular FormulaC29H29F6N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)=O)(C)C=2C(=CC(=NC2)N3CCOCC3)C4=C(C)C=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bignami F, et al. NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94.?
molnova catalog
related products
-
4-Oxoisotretinoin
4-oxo-isotretinoin is the major blood metabolite.
-
Neurokinin A(4-10)
Neurokinin A (4-10) is a tachykinin NK2 receptor agonist. A structure-activity study of the neurokinin A (NKA) fragment NKA(4-10) was performed to investigate the importance of amino acid residues for receptor efficacy, potency and affinity at the NK2 receptor in human colon circular muscle.
-
(R)-CJ 11974
(R)-CJ 11974 is a novel non-peptide neurokinin NK1 substance P receptor antagonist with potential analgesic activity that can be used to study chemotherapy-induced vomiting.
